NPM1 and acute myeloid leukemia: The early result of phase I/II study investigating oral combination of revumenib with decitabine/cedazuridine (ASTX727) and venetoclax has demonstrated high efficacy in AML patients with KMT2A‐r, NPM1 mutations, and NUP98‐r.166